Resources
Most of what we do is not available publicly, but we’re proud of what we can share
Nuturing the Potential of the Biosimilar Market
Is the biosimilars market working? Apteka was commissioned by Alliance for Patient Access and the Biologics Prescribers Collaborative to examine if, almost a decade since the first approved biosimilar in the U.S., are biosimilars are achieving three objectives: (1) decreasing costs to the overall health care system, (2) increasing patient access/options, and (3) reducing patient cost sharing.
Beyond those objectives, what are the barriers to realizing the full potential of biosimilars? What policies have helped or hindered the market, and are some payers doing better than others? And, given the findings, what are the recommendations that would lead to a more stable and robust biosimilar market?
Hope for the Best, Prepare for the Worst: IRA’s Unintended Consequences for Part D
The IRA enacted the most significant changes to Part D since its inception, and these reforms have major implications for Medicare beneficiaries. In this new paper, the MAPRx Coalition examines the potential impact of three of IRA’s major Part D provisions.
